Ibtissem Oueslati

Dr. Ibtissem Oueslati

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
FCFaten Cherchir
Faten Cherchir
IOIbtissem Oueslati
Ibtissem Oueslati
MYMeriem Yazidi
Meriem Yazidi
FCFatma Chaker
Fatma Chaker
HMHabiba Mizouni
Habiba Mizouni
MCMelika Chihaoui
Melika Chihaoui

23 March 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MYMeriem Yazidi
Meriem Yazidi
SMSana Mahjoubi
Sana Mahjoubi
IOIbtissem Oueslati
Ibtissem Oueslati
FCFatma Chaker
Fatma Chaker
MCMelika Chihaoui
Melika Chihaoui
Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between [...] ABSTRACT Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between

7 May 2022 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
IOIbtissem Oueslati
Ibtissem Oueslati
AKAsma Kardi
Asma Kardi
FBFatma Boukhayatia
Fatma Boukhayatia
BHBassem Hammami
Bassem Hammami
MCMeriem Cheikh
Meriem Cheikh
MCMelika Chihaoui
Melika Chihaoui

19 June 2023 in Chronic Illness
Verified
Journal Article
Closed access
MYMeriem Yazidi
Meriem Yazidi
EKElyes Kamoun
Elyes Kamoun
STSameh Hadj Taieb
Sameh Hadj Taieb
OROns Rejeb
Ons Rejeb
SMSonia Mahjoub
Sonia Mahjoub
MCMelika Chihaoui
Melika Chihaoui
Objectives: To determine the prevalence of vitamin B12 deficiency in a Tunisian population with type 2 diabetes (T2D) on metformin treatment for more than three years and to identify its risk factors. Methods: This is a cross-sectional study conducted on 257 patients with T2D treated with metformin for at least three years. Patients were divided into two groups according to their vitamin B12 status. Low vitamin B12 was defined as ≤ 203 pg/mL. Results: The mean age of the patients was 59.8 ± 7.9 years. The mean duration of metformin use was 10.2 ± 5.2 years. The mean vitamin B12 level was 294.9 ± 156.4 pg/mL. The prevalence of vitamin B12 deficiency was 28.4%. Male gender, HbA1c < 7% and hyperhomocysteinemia were significantly associated with vitamin B12 deficiency (respectively p = 0.02, p < 0.001, p < 0.001). Homocysteine level was negatively correlated with vitamin B12 level ( r = −0.2, p = 0.001). Dose and duration of metformin treatment, peripheral neuropathy and anemia were not associated with vitamin B12 deficiency. On multivariate analysis, HbA1c < 7% and hyperhomocysteinemia were independently associated with vitamin B12 deficiency (respectively OR = 3.2, 95%CI = [1.6–6.3] and OR = 2.3, 95%CI = [1.2–4.2]). Discussion: The prevalence of vitamin B12 deficiency in patients with T2D on metformin treatment was high. Hyperhomocysteinemia is associated with vitamin B12 deficiency suggesting that the deficit occurs at the tissue level.

20 July 2024 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
MYMeriem Yazidi
Meriem Yazidi
EKElyes Kammoun
Elyes Kammoun
IOIbtissem Oueslati
Ibtissem Oueslati
MCMelika Chihaoui
Melika Chihaoui
Metformin is the most widely used antihyperglycemic drug in patients with type 2 diabetes (T2D). Over the past 2 decades, several studies have highlighted a substantial increase in the risk of vitamin B12 deficiency in patients with T2D on metformin therapy. This can lead to several complications and induce or exacerbate peripheral neuropathy. Despite these data, there are no definite guidelines for screening, diagnosing, and treating vitamin B12 deficiency in patients with T2D on metformin therapy. Therefore, in this narrative review, we aimed to suggest a practical diagnostic and therapeutic strategy to address vitamin B12 deficiency in patients with T2D receiving metformin treatment. Clinical evidence supporting an increased risk of vitamin B12 deficiency in patients with T2D on metformin therapy and its risk factors and potential complications are also discussed.

15 September 2023 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
FCFaten Cherchir
Faten Cherchir
IOIbtissem Oueslati
Ibtissem Oueslati
MYMeriem Yazidi
Meriem Yazidi
FCFatma Chaker
Fatma Chaker
MCMelika Chihaoui
Melika Chihaoui